AriBio's 'Oral Alzheimer's Drug' Phase 3 Results Near, Beneficiary Stocks Draw Attention

AR1001 Trial Results to Be Revealed at U.S. Conference on the 16th
AriBio Holdings and Other Affiliates Draw Attention
Samjin Pharmaceutical's Domestic Sales Rights and Mason Capital's Equity Investment

With AriBio, which is developing the oral Alzheimer's disease treatment AR1001, preparing to announce topline data from its global Phase 3 trial, attention is also turning to stocks that could benefit from the results. Because direct investment in AriBio, an unlisted company, is limited, listed companies that have already secured equity stakes and business partnerships with the company are naturally being reassessed as potential beneficiaries.

According to industry sources on November 9, AriBio is conducting a final analysis of data ahead of the release of key results from POLARIS-AD, its global Phase 3 trial in patients with early Alzheimer's disease. The results are expected to be a major hurdle, determining not only whether the company can file for approval with the U.S. Food and Drug Administration (FDA), but also whether it can move into full-scale global commercialization. Existing injectable treatments have shown limitations in terms of side effects and ease of administration. Analysts say that if AR1001, an oral formulation, proves effective and safe, its competitiveness in the global market will rise significantly.

AriBio Lab, a listed affiliate, is seen as a potential direct beneficiary. Since AriBio is unlisted, the market views AriBio Lab, which has the closest equity and business ties to the company, along with AriBio's largest shareholder, AriBio Holdings, as a key avenue for capturing the full impact of the drug development momentum. In particular, expectations are building that synergies among the affiliates will gain momentum during the approval and commercialization process following the release of the Phase 3 data.

Traditional pharmaceutical companies that have secured significant stakes alongside business partnerships are also emerging as potential beneficiaries. Samjin Pharmaceutical, AriBio's second-largest shareholder, has already invested in the company and signed an agreement to jointly conduct a domestic Phase 3 trial of AR1001, as well as a KRW 100 billion contract granting it exclusive rights to manufacture and sell the drug in South Korea. Analysts say that if the clinical data are positive and the drug moves toward commercialization, the value of Samjin Pharmaceutical's stake could rise, while revenue from exclusive production and distribution of the finished product could begin in earnest.

Mason Capital, which made an early investment, is also drawing attention. Mason Capital, a financial affiliate of Sillajen, formed a consortium with private equity firm Cactus Private Equity in 2022 and participated in AriBio's third-party allotment of new shares, acquiring a stake through a fund worth about KRW 30 billion. If a revaluation of AriBio following successful clinical trials and its initial public offering (IPO) become more likely, Mason Capital is also expected to attract market attention as it realizes substantial gains on its equity stake and recovers its investment.

An industry source said, "When a large global clinical trial by an unlisted drug developer is announced, market attention tends to focus on investors that secured stakes early and listed partners that secured licensing rights, because direct investment is limited." The source added, "If the data demonstrate efficacy, expectations for gains from the revaluation of equity stakes and for improved earnings from future commercialization could spread across related listed companies."

This content was produced with the assistance of AI translation services.